Johnson & Johnson (JNJ) Change in Receivables (2009 - 2026)
Johnson & Johnson (JNJ) posted Change in Receivables of $595.0 million for Q1 2026, up 252.17% sequentially from -$391.0 million in Q4 2025, and down 35.75% YoY from $926.0 million in Q1 2025.
Johnson & Johnson (JNJ) Change in Receivables (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Change in Receivables data on file, last reported at $595.0 million in Q1 2026.
- Quarterly Change in Receivables fell 35.75% year-over-year to $595.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 37.7% YoY) and the FY2025 annual result came in at $1.8 billion, up 338.67% from the prior year.
- Change in Receivables climbed to $595.0 million in Q1 2026 per JNJ's latest filing, from -$391.0 million in the prior quarter.
- The five-year high for Change in Receivables was $1.4 billion in Q2 2025, with the low at -$853.0 million in Q4 2024.
- Average Change in Receivables over 5 years is $220.3 million, with a median of $252.0 million recorded in 2023.
- The widest YoY moves for Change in Receivables: up 416.67% in 2024, down 275.77% in 2024.
- Johnson & Johnson's Change in Receivables stood at $427.0 million in 2022, then plunged by 153.16% to -$227.0 million in 2023, then tumbled by 275.77% to -$853.0 million in 2024, then surged by 54.16% to -$391.0 million in 2025, then soared by 252.17% to $595.0 million in 2026.
- Business Quant data shows JNJ's Change in Receivables at $595.0 million in Q1 2026, -$391.0 million in Q4 2025, and -$111.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 595.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -87.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -413.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -134.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | -103.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 595.00 Mn |
| Mar 29, 2026 | 595.00 Mn |
| Dec 28, 2025 | -391.00 Mn |
| Dec 28, 2025 | -391.00 Mn |
| Sep 28, 2025 | -111.00 Mn |
| Sep 28, 2025 | -111.00 Mn |
| Jun 29, 2025 | 1.36 Bn |
| Jun 29, 2025 | 1.36 Bn |
| Mar 30, 2025 | 926.00 Mn |
| Mar 30, 2025 | 926.00 Mn |
| Dec 29, 2024 | -853.00 Mn |
| Dec 29, 2024 | -853.00 Mn |
| Sep 29, 2024 | 96.00 Mn |
| Sep 29, 2024 | 96.00 Mn |
| Jun 30, 2024 | 884.00 Mn |
| Jun 30, 2024 | 884.00 Mn |
| Mar 31, 2024 | 279.00 Mn |
| Mar 31, 2024 | 279.00 Mn |
| Dec 31, 2023 | -227.00 Mn |
| Dec 31, 2023 | -227.00 Mn |